Mineralys Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US6031701013 (MLYS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    0 / 7

    Profile

    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€174.32M
    EBIT margin
    0.0%
    Net income
    -€163.77M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €9.66M +∞% -€166.61M +1.7%
    €77.71M +704.7% -€187.60M +12.6%
    €260.05M +234.7% -€65.73M -65.0%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Rodman David Malcom Chief Medical Officer -11K $12.93 -$146.95K
    Levy Adam Scott CFO and Secretary -74K $14.62 -$1.08M

    Earnings Calls

    Latest earnings call: May 9, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 177K $2.82M +58K Buy

    Add to watchlist

    Notifications